Do you want to read an article? Please log in or register.
Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
Asthma
Related content
RECOMMENDED
Asthma
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
J Allergy Clin Immunol.
Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H
doi: 10.1016/j.jaci.2018.09.033.
RECOMMENDED
Further Publications
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE, Chaudhuri R, Pavord ID, Heaney LG, Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium).
doi: 10.1016/S2213-2600(21)00004-7
RECOMMENDED
Asthma
Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Prazma CM, Idzko M, Douglass JA, Bourdin A, Mallett S, Albers FC, Yancey SW
doi: 10.2147/JAA.S298559
RECOMMENDED
Asthma
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison
J Allergy Clin Immunol.
Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB
doi: 10.1016/j.jaci.2018.08.031.
Asthma
Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
Drug Des Devel Ther.
Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G
doi: 10.2147/
RECOMMENDED
Asthma
Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Puggioni F, Brussino L, Canonica GW, Blasi F, Paggiaro P, Caminati M, Latorre M, Heffler E, Senna G, Severe Asthma Network in Italy (SANI) group.
doi: 10.2147/JAA.S274245
Asthma
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Lancet Respir Med.
Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A
doi: 10.1016/
RECOMMENDED
Asthma
Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials: Bridging Clinical and Patient Perspectives
Am J Respir Crit Care Med.
Siddiqui S, Denlinger LC, Fowler SJ, Akuthota P, Shaw DE, Heaney LG, Brown L, Castro M, Winders TA, Kraft M, Wagers S, Peters MC, Pavord ID, Walker S, Jarjour NN
doi: 10.1164/rccm.
Asthma
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
Allergy.
Chapman KR, Albers FC, Chipps B, Muñoz X, Devouassoux G, Bergna M, Galkin D, Azmi J, Mouneimne D, Price RG, Liu MC
doi: 10.1111/all.13850.